The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate

Prostate

Volumn 67, Issue 10, 2007, Pages 1132-1142

  Whittington, Kate ^a   Connors, Belinda ^a   King, Keith ^b   Assinder, Steve ^b,c   Hogarth, Karole ^b   Nicholson, Helen ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Androgen; Cell proliferation; Estrogen; Oxytocin; Prostate disease

Indexed keywords

ANDROGEN; ESTROGEN; OXYTOCIN; OXYTOCIN RECEPTOR; SEX HORMONE; TESTOSTERONE;

ARTICLE; CANCER CELL CULTURE; CAVEOLA; CELL MEMBRANE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; HORMONE ACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN LOCALIZATION; STROMA CELL;

AGING; ANDROGENS; CAVEOLAE; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; EPITHELIAL CELLS; HUMANS; MALE; OXYTOCIN; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, OXYTOCIN; TESTOSTERONE;

EID: 34250854026     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20612     Document Type: Article

References (40)

1. Davies P, Eaton CL. Regulation of prostate growth. J Endocrinol 1991;131:5-17.
2. Medh RD, Thompson EB. Hormonal regulation of physiological cell turnover and apoptosis. Cell Tissue Res 2000;301:101-124.
3. Ball EMA, Risbridger GP. New perspectives on growth factor-sex steroid interaction in the prostate. Cytokine Growth Factor Rev 2003;14:5-16.
4. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular and molecular control of prostatic development. Dev Biol 2003;253:165-174.
5. Bayne CW, Donnelly F, Chapman K, Bollina P, Buck C, Habib F. A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase. J Clin Endocrinol Metab 1998;83:206-213.
6. Byrne RL, Leung H, Neal DE. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. BJU Int 1996;77:627-633.
7. Nicholson HD, Jenkin L. Oxytocin and prostatic function. Adv Exp Med Biol 1995;395:529-537.
8. Ivell R, Balvers M, Rust W, Bathgate R, Einspanier A. Oxytocin and male reproductive function. Adv Exp Med Biol 1997;424:253-264.
9. Farina-Lipari E, Lipari D, Bellafiore M, Arizalone R, Cappello F, Valentino B. Presence of atrial natriuretic factor in normal and hyperplastic human prostate and its relationship with oxytocin localization. Eur J Histochem 2003;47:133-138.
10. Whittington K, Assinder SJ, Gould M, Nicholson HD. Oxytocin, oxytocin associated neurophysin and the oxytocin receptor in the human prostate. Cell Tissue Res 2004;318:375-382.
11. Bodanszky M, Sharaf H, Roy JB, Said SI. Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate. Eur J Pharmacol 1992;216:311-313.
12. Morita T, Shibata K, Kikkawa F, Kajiyama H, Ino K, Mizutani S. Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer 2004;109(4):525-532.
13. Novak JF, Judkins MB, Chernin MI, Cassoni P, Bussolati G, Nitche JA, Nishimoto SK. A plasmin-derived hexapeptide from the carboxyl end of osteocalcin counteracts oxytocin-mediated growth inhibition of osteosarcoma cells. Cancer Res 2000;60:3470-3476.
14. Cassoni P, Sapino A, Fortunati N, Munaron L, Chini B, Bussolati G. Oxytocin inhibits the proliferation of MDA-MB231 human breast cancer cells via cyclic adenosine monophosphate and protein kinase A. Int J Cancer 1997;72:340-344.
15. Cassoni P, Sapino A, Stella A, Fortunati N, Bussolati G. Presence and significance of oxytocin receptors in human neuroblastomas and glial tumours. Int J Cancer 1998;77:695-700.
16. Cassoni P, Sapino A, Munaron L, Deaglio S, Chini B, Graziani A, Ahmed A, Bussolati G. Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. Endocrinology 2001;142:1130-1136.
17. Petersson M, Lagumdzija A, Stark A, Bucht E. Oxytocin stimulates proliferation of human osteoblast-like cells. Peptides 2002;23:1121-1126.
18. Péqueux C, Breton C, Hendrick JC, Hagelstein MT, Martens H, Winkler R, Geenen V, Legros JJ. Oxytocin synthesis and oxytocin receptor expression by cells of human small cell carcinoma of the lung stimulate tumour growth through autocrine/paracrine signalling. Cancer Res 2002;62:4623-4629.
19. Cassoni P, Sapino A, Deaglio S, Bussolati B, Volante M, Munaron L, Albini A, Torrisi A, Bussolati G. Oxytocin is a growth factor for Kaposi's sarcoma cells: Evidence of endocrine-immunological cross-talk. Cancer Res 2002;62:2406-2413.
20. Lucas RL, Salm AK. Astroglia proliferate in response to oxytocin and vasopressin. Brain Res 1995;618:218-222.
21. Armstrong DT, Hansel W. 1958; Effects of hormone treatment on testis development and pituitary function. Int J Fertility 1958;3:296-306.
22. Plecas B, Popovic A, Jovovic D, Hristic M. Mitotic activity and cell deletion in ventral prostate epithelium of intact and castrated oxytocin-treated rats. J Endocrinol Invest 1992;15:249-253.
23. Cassoni P, Marrocco T, Sapino A, Allial E, Bussolati G. Evidence of oxytocin/oxytocin receptor interplay in human prostate gland and carcinomas. Int J Oncology 2004;25:899-904.
24. King K, Nicholson HD, Assinder SJ. Effect of increasing ratio of estrogen: Androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP. Prostate 2006;66:105-114.
25. Nicholson HD, Guldenaar SEF, Boer GJ, Pickering BT. Testicular oxytocin: Effects of intratesticular oxytocin in the rat. J Endocrinol 1991;130:231-238.
26. Assinder SJ, Johnson C, King K, Nicholson HD. Regulation of 5α-reductase isoforms by oxytocin in the rat ventral prostate. Endocrinology 2004;145:5767-5773.
27. Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, Kawabe Y, Honma S, Yamanaka H. Changes in the endocrine environment of the human prostate transition zone with aging: Simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 2000;42:45-55.
28. Ho SM. Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J Cellular Biochem 2004;91:495-503.
29. Jenkin L, Nicholson HD. Evidence for the regulation of prostatic oxytocin by gonadal steroids in the rat. J Androl 1999;20:80-87.
30. Assinder SJ, Nicholson HD. Effects of steroids on oxytocin secretion by the human prostate in vitro. Int J Androl 2004;27:12-18.
31. Nicholson HD. Oxytocin, a paracrine regulator of prostatic function. Rev Reprod 1996;1:69-72.
32. Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: Comparisons with Atosiban. Int J Pept Protein Res 1995;46:244-252.
33. Guzzi F, Zanchetta D, Cassoni P, Guzzi V, Francolini M, Parenti M, Chini B. Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene 2002;21:1658-1667.
34. Foster CS. Pathology of benign prostatic hyperplasia. Prostate Suppl 2000;9:4-14.
35. Reversi A, Rimoldi V, Marrocco T, Cassoni P, Bussolati G, Parenti M, Chini B. The oxytocin receptor antagonist Atosiban inhibits cell growth via a biased agonist mechanism. J Biol Chem 2005;280:16311-16318.
36. Blok LJ, Kumar MV, Tindall DJ. Isolation of cDNA's that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR. Prostate 1995;26:213-224.
37. Lyng FM, Jones GR, Rommerts FFG. Rapid androgen actions on calcium signaling in rat Sertoli cells and two human prostatic cell lines: Similar biphasic responses between 1 picomolar and 100 nanomolar concentrations. Biol Reprod 2000;63:736-747.
38. Stathopoulos EN, Dambaki C, Kampa M, Theodoropoulos PA, Anezinis P, Delekas D, Delides GS, Castanas E. Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells. BMC Clin Pathol 2003;3:1-9.
39. Ostrom RS, Insel PA. The evolving role of lipid rafts and caveolae in G protein-coupled receptor signalling: Implications for molecular pharmacology. Br J Pharmacol 2004;143:235-245.
40. Rimoldi V, Reversi A, Taverna E, Rosa P, Francolini M, Cassoni P, Chini B. Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene 2003;22:6054-6060.